Reweighting Oranges to Apples: Transported RE-LY Trial Versus Nonexperimental Effect Estimates of Anticoagulation in Atrial Fibrillation

被引:12
|
作者
Webster-Clark, Michael [1 ]
Lund, Jennifer L. [1 ]
Sturmer, Til [1 ]
Poole, Charles [1 ]
Simpson, Ross J. [2 ]
Edwards, Jessie K. [1 ]
机构
[1] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA
[2] Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA
基金
美国国家卫生研究院;
关键词
Anticoagulation; Generalizability; Medicare; Older adults; Transportability; CLINICAL-TRIALS; ORAL ANTICOAGULANTS; STROKE PREVENTION; ADVERSE EVENTS; WARFARIN; DABIGATRAN; RIVAROXABAN; APIXABAN; OUTCOMES; THERAPY;
D O I
10.1097/EDE.0000000000001230
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Results from trials and nonexperimental studies are often directly compared, with little attention paid to differences between study populations. When target and trial population data are available, accounting for these differences through transporting trial results to target populations of interest provides useful perspective. We aimed to compare two-year risk differences (RDs) for ischemic stroke, mortality, and gastrointestinal bleeding in older adults with atrial fibrillation initiating dabigatran and warfarin when using trial transport methods versus nonexperimental methods. Methods: We identified Medicare beneficiaries who initiated warfarin or dabigatran from a 20% nationwide sample. To transport treatment effects observed in the randomized evaluation of long-term anticoagulation trial, we applied inverse odds weights to standardize estimates to two Medicare target populations of interest, initiators of: (1) dabigatran and (2) warfarin. Separately, we conducted a nonexperimental study in the Medicare populations using standardized morbidity ratio weighting to control measured confounding. Results: Comparing dabigatran to warfarin, estimated two-year RDs for ischemic stroke were similar with trial transport and nonexperimental methods. However, two-year mortality RDs were closer to the null when using trial transport versus nonexperimental methods for the dabigatran target population (transported RD: -0.57%; nonexperimental RD: -1.9%). Estimated gastrointestinal bleeding RDs from trial transport (dabigatran initiator RD: 1.8%; warfarin initiator RD: 1.9%) appeared more harmful than nonexperimental results (dabigatran initiator RD: 0.14%; warfarin initiator RD: 0.57%). Conclusions: Differences in study populations can and should be considered quantitatively to ensure results are relevant to populations of interest, particularly when comparing trial with nonexperimental findings. See video abstract:.
引用
收藏
页码:605 / 613
页数:9
相关论文
共 50 条
  • [31] Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation Results From the RE-LY Trial
    Stam-Slob, Manon C.
    Connolly, Stuart J.
    van der Graaf, Yolanda
    van der Leeuw, Joep
    Dorresteijn, Jannick A. N.
    Eikelboom, John W.
    Peters, Ron J. G.
    Alings, Marco
    Visseren, Frank L. J.
    CIRCULATION, 2019, 139 (25) : 2846 - 2856
  • [32] D-dimer and factor Vila in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy A RE-LY substudy
    Siegbahn, Agneta
    Oldgren, Jonas
    Andersson, Ulrika
    Ezekowitz, Michael D.
    Reilly, Paul A.
    Connolly, Stuart J.
    Yusuf, Salim
    Wallentin, Lars
    Eikelboom, John W.
    THROMBOSIS AND HAEMOSTASIS, 2016, 115 (05) : 921 - 930
  • [33] Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial
    Hijazi, Ziad
    Verdecchia, Paolo
    Oldgren, Jonas
    Andersson, Ulrika
    Reboldi, Gianpaolo
    Di Pasquale, Giuseppe
    Mazzotta, Giovanni
    Angeli, Fabio
    Eikelboom, John W.
    Ezekowitz, Michael D.
    Connolly, Stuart J.
    Yusuf, Salim
    Wallentin, Lars
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (02):
  • [34] Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial
    Westenbrink, B. D.
    Alings, M.
    Connolly, S. J.
    Eikelboom, J.
    Ezekowitz, M. D.
    Oldgren, J.
    Yang, S.
    Pongue, J.
    Yusuf, S.
    Wallentin, L.
    van Gilst, W. H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (05) : 699 - 707
  • [35] The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)
    Reilly, Paul A.
    Lehr, Thorsten
    Haertter, Sebastian
    Connolly, Stuart J.
    Yusuf, Salim
    Eikelboom, John W.
    Ezekowitz, Michael D.
    Nehmiz, Gerhard
    Wang, Susan
    Wallentin, Lars
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (04) : 321 - 328
  • [36] Growth differentiation factor 15 is an independent marker of risk of major bleeding in atrial fibrillation: insights from the RE-LY trial
    Hijazi, Z.
    Oldgren, J.
    Andersson, U.
    Connolly, S. J.
    Eikelboom, J. W.
    Ezekowitz, M. D.
    Reilly, P. A.
    Siegbahn, A.
    Yusuf, S.
    Wallentin, L.
    EUROPEAN HEART JOURNAL, 2016, 37 : 429 - 429
  • [37] Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial
    Diener, Hans Chnstoph
    Connolly, Stuart J.
    Ezekowitz, Michael D.
    Wallentin, Lars
    Reilly, Paul A.
    Yang, Sean
    Xavier, Denis
    Di Pasquale, Giuseppe
    Yusuf, Salim
    LANCET NEUROLOGY, 2010, 9 (12): : 1157 - 1163
  • [38] Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation - a RE-LY Trial Analysis
    Hijazi, Ziad
    Hohnloser, Stefan H.
    Oldgren, Jonas
    Andersson, Ulrika
    Connolly, Stuart J.
    Eikelboom, John W.
    Ezekowitz, Michael D.
    Reilly, Paul A.
    Siegbahn, Agneta
    Yusuf, Salim
    Wallentin, Lars
    CIRCULATION, 2013, 128 (22)
  • [39] Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial
    Hijazi, Ziad
    Oldgren, Jonas
    Andersson, Ulrika
    Connolly, Stuart J.
    Eikelboom, EJohn W.
    Ezekowitz, Michael D.
    Reilly, Paul A.
    Yusuf, Salim
    Siegbahn, Agneta
    Wallentin, Lars
    AMERICAN HEART JOURNAL, 2017, 190 : 94 - 103
  • [40] DABIGATRAN VERSUS WARFARIN AND IMPACT OF CHAD2-VASC SCORE ON OUTCOME IN ATRIAL FIBRILLATION PATIENTS: A RE-LY SUBGROUP ANALYSIS
    Oldgren, Jonas
    Ezekowitz, Michael D.
    Alings, Marco
    Diener, Hans-Christoph
    Reilly, Paul A.
    Yusuf, Salim
    Wallentin, Lars
    Connolly, Stuart
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E7 - E7